Are Brain Interfaces Finally Ready For Daily Life? | Longevity News Roundup — Week 23, 2026

Are Brain Interfaces Finally Ready For Daily Life? | Longevity News Roundup — Week 23, 2026

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: partners.fatty15.com/UNLOCKED [https://partners.fatty15.com/UNLOCKED] ---------- In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine wearable health innovation, brain-computer interfaces, physician-led longevity care, Alzheimer’s research, and the evolution of the longevity industry. * ŌURA launched Ring 5, a redesigned device that is 40% smaller while maintaining week-long battery life. New features include blood pressure signals, breathing monitoring, GLP-1 insights, and integrated health data designed to make wearables a central health management platform. * Ability Neurotech received approval in the Netherlands to begin long-term studies of its battery-free optical brain implant in ALS patients. The system is designed for everyday home use, highlighting the industry's shift from laboratory demonstrations toward real-world functionality. * Elysium Health launched The Elysium Longevity Institute (TELI), combining physician oversight, advanced testing, supplements, prescriptions, and peptides. The move reflects a broader trend of established longevity brands expanding into comprehensive clinical care. * A study of 69 women aged 65 and older linked poor sleep, increased Alzheimer’s genetic risk, greater tau accumulation, and weaker visual memory. Researchers suggest sleep and visual memory changes may offer valuable signals of early disease processes. * From 95 startups across 32 countries entering the Longevity Show pitch competition to growing investment in diagnostics, prevention platforms, AI, and care delivery, the sector is increasingly focused on translating science into scalable healthspan solutions. * The broader transition from sick care to prevention-led systems, where aging biology becomes a core risk factor and healthspan metrics replace disease counting. Insurance, pensions, and healthcare payment models need to adapt as longevity becomes embedded in economic infrastructure, not just products. ---------- News & References: * What poor sleep may be telling women about Alzheimer’s? → https://longevity.technology/news/what-poor-sleep-may-be-telling-women-about-alzheimers/ [https://longevity.technology/news/what-poor-sleep-may-be-telling-women-about-alzheimers/] * Five finalists advance in longevity pitch contest → https://longevity.technology/news/five-finalists-advance-in-longevity-pitch-contest/ [https://longevity.technology/news/five-finalists-advance-in-longevity-pitch-contest/] * ŌURA’s smallest smart ring launched with expanded health monitoring → https://longevity.technology/news/ouras-smallest-smart-ring-launched-with-expanded-health-monitoring/ [https://longevity.technology/news/ouras-smallest-smart-ring-launched-with-expanded-health-monitoring/] * Optical brain implant moves into real-world use → https://longevity.technology/news/optical-brain-implant-moves-into-real-world-use/ [https://longevity.technology/news/optical-brain-implant-moves-into-real-world-use/] * Elysium expands into physician-led longevity care → https://longevity.technology/news/elysium-expands-into-physician-led-longevity-care/ [https://longevity.technology/news/elysium-expands-into-physician-led-longevity-care/] * Public health faces longevity imperative → https://longevity.technology/news/public-health-faces-longevity-imperative/ [https://longevity.technology/news/public-health-faces-longevity-imperative/]

Dezawa MuseCells® Explained: The Next Generation of Regenerative Medicine?

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: MuseCell Innovations MuseCell Innovations is a science-backed regenerative medicine company developing patented Dezawa MuseCells®, unique stem cells that support the body's natural repair and regeneration processes. Benefits include cellular renewal, tissue repair, healthy aging, improved resilience, and overall wellbeing. Click the link below to explore the science, research, and technology behind this innovative approach to regenerative medicine. Link: musecellinnovations.com [https://musecellinnovations.com/] ---------- Guests: Dominik Duscher MD PhD President & Chief Executive Officer at MuseCell Innovations Instagram: www.instagram.com/dr.dominikduscher/ [https://www.instagram.com/dr.dominikduscher/] Website: musecellinnovations.com [https://musecellinnovations.com/] Dr. Jeffrey J. Wiegers Chief Medical Officer at MuseCell Innovations Instagram: www.instagram.com/jeffwiegers [https://www.instagram.com/jeffwiegers/] Website: musecellinnovations.com [https://musecellinnovations.com/] ---------- What if a naturally occurring stem cell subpopulation could home to sites of injury and support tissue repair across multiple indications? Phil Newman and Dr. Nina Patrick sit down with Dr. Dominik Duscher, MD PhD, President and CEO of MuseCell Innovations, and Dr. Jeffrey Wiegers, MD, Chief Medical Officer, to explore the unique properties of Dezawa MuseCells®. In this session, they describe these cells as highly enriched in a purified product with pluripotent-like potential, signaling that enables targeted homing, and immune tolerance that supports allogeneic use without major immune activation, based on early human experience. From first-in-human intravenous use in acute myocardial infarction showing safety and encouraging left ventricle performance signals, to randomized placebo-controlled subacute ischemic stroke data showing higher response rates than placebo, they walk through human trial experience without overstating effects. They also discuss repeated intravenous dosing in an amyotrophic lateral sclerosis study suggesting stabilizing signal with minimal adverse events, single-arm spinal cord injury data, and early work in neonatal hypoxic-ischemic encephalopathy showing recovery signals in some infants. They also address broader practicalities around manufacturing rigor, quality control, and provider competency as determinants of safety in clinical settings, and they describe the need for clear documentation and oversight to avoid unlicensed or inferior products. In this episode, you’ll learn: * Why pluripotency, homing ability, and immune tolerance are considered key features of Dezawa MuseCells® and how these properties may relate to tissue repair. * What early human studies in conditions like heart attack, stroke, ALS, spinal cord injury, and neonatal brain injury have shown in terms of safety and early clinical signals. * Why manufacturing quality, purification, and standardization are critical for consistency and safety in cell-based therapies. * Why clinician expertise and proper oversight matter when these therapies move from research into clinical use. * How to think about verifying product authenticity and avoiding unregulated or non-standard cell therapies. If you want to understand the biological features, emerging human data, and practical considerations around Dezawa MuseCells® as discussed by leaders in the field, this episode connects cellular biology with real-world context for regenerative medicine and longevity. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

Sam Altman's $1.8B Longevity Company, CRISPR & AI Health | Longevity News Roundup — Week 22, 2026

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [ https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: https://partners.fatty15.com/UNLOCKED [https://partners.fatty15.com/UNLOCKED] ---------- In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine FDA-cleared sleep diagnostics, safer CRISPR therapies, longevity clinic accountability, Retro Biosciences’ valuation, and AI-driven preventative healthcare. * Sunrise received FDA clearance for Sunrise Air, a rechargeable at-home sleep apnea diagnostic using a chin sensor for multi-night testing. The device tracks airflow, oxygen, pulse, and snoring while targeting underdiagnosis linked to cardiovascular and cognitive decline. * Insilico and Human Longevity have announced a multimillion-dollar collaboration to build what they describe as the industry’s first large-scale AI foundation model dedicated to longevity science.  * Daewoong Pharmaceutical acquired Turn Biotechnologies’ partial reprogramming assets, including its ERA mRNA platform. The deal gives longevity-focused age reversal IP a new clinical and regulatory pathway. * Scribe Therapeutics presented preclinical ELXR CRISPR data showing 18-month cholesterol reduction in primates through epigenetic PCSK9 silencing. The platform reduced off-target activity by up to 100-fold without permanently altering DNA. * At the Milan Longevity Summit 2026 they explored how longevity clinics are moving from wellness branding toward evidence-based preventative medicine. Clinics are increasingly being pressured to prove outcomes through validated biomarkers and longitudinal patient data. * Retro Biosciences reached a $1.8 billion valuation while advancing an Alzheimer’s drug into human trials. Retro’s approach focuses on boosting a natural cellular process called autophagy, essentially the body’s built-in recycling program. ---------- News & References: * Retro Bio’s $1.8b moment: Hopes up as Alzheimer’s trial advances → https://longevity.technology/news/retro-bios-1-8b-moment-hopes-up-as-alzheimers-trial-advances/ [https://longevity.technology/news/retro-bios-1-8b-moment-hopes-up-as-alzheimers-trial-advances/] * Longevity clinics face their proving ground → https://longevity.technology/news/longevity-clinics-face-their-proving-ground/ [https://longevity.technology/news/longevity-clinics-face-their-proving-ground/] * Sunrise receives FDA clearance for rechargeable at-home sleep test → https://longevity.technology/news/sunrise-receives-fda-clearance-for-rechargeable-at-home-sleep-test/ [https://longevity.technology/news/sunrise-receives-fda-clearance-for-rechargeable-at-home-sleep-test/] * Daewoong acquires Turn Bio age-reversal assets → https://longevity.technology/news/daewoong-acquires-turn-bio-age-reversal-assets/ [https://longevity.technology/news/daewoong-acquires-turn-bio-age-reversal-assets/] * Scribe Therapeutics debuts CRISPR platforms for cholesterol treatment → https://longevity.technology/news/scribe-therapeutics-debuts-crispr-platforms-for-cholesterol-treatment/ [https://longevity.technology/news/scribe-therapeutics-debuts-crispr-platforms-for-cholesterol-treatment/] * Insilico and Human Longevity eye to predict disease early with AI → https://longevity.technology/news/insilico-and-human-longevity-eye-to-predict-disease-early-with-ai/ [https://longevity.technology/news/insilico-and-human-longevity-eye-to-predict-disease-early-with-ai/]

This Wearable Tracks the Female Cycle in Real Time

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: fatty15.com/UNLOCKED [https://fatty15.com/UNLOCKED] ---------- Guests: Jenny Duan Co-Founder and CEO of Clair Health LinkedIn: https://www.linkedin.com/in/jennysduan/ [https://www.linkedin.com/in/jennysduan/] Website: https://wearclair.com/ [https://wearclair.com/] Abhinav Agarwal Co-Founder and CTO of Clair Health LinkedIn: https://www.linkedin.com/in/agarwalaabhinav/ [https://www.linkedin.com/in/agarwalaabhinav/] Website: https://wearclair.com/ [https://wearclair.com/] ---------- What if women’s hormones were tracked like heart rate, continuously and contextually, not through annual snapshots? Phil Newman and Dr. Nina Patrick sit down with Jenny Duan, CEO of Clair, and Abhinav Argawal, CTO, to explore how a jewelry-inspired wrist wearable uses multi-sensor biosignals to infer estrogen and progesterone in real time across daily life. They explain how signals such as skin temperature, HRV, sweat response, intracellular and extracellular current shifts, and more than 100 derived biomarkers are combined through sensor fusion to model hormone trajectories that update throughout the day. From forecasting an athlete’s rate of perceived exertion days before training to identifying progesterone patterns associated with PCOS and endometriosis risk, these examples show what continuous data reveals that snapshot testing cannot. The discussion also uncovers how this level of visibility allows the female cycle to be understood as nine distinct sub-phases rather than the traditional four. They also discuss how lifestyle context, such as sleep, hydration, stress, and schedule, is integrated into the model to avoid contradictions between device feedback and lived experience. Early beta studies across PCOS, endometriosis, and perimenopause cohorts are already informing how this data can support fertility planning and symptom awareness. In this episode, you’ll learn: * Why the female cycle can be divided into nine hormone sub-phases * How 230 biomarkers are refined into 100 inputs for hormone modeling * How athletes can adjust hydration and nutrition before exertion spikes * How progesterone trends may signal risk patterns for PCOS and endometriosis * Why fertility and perimenopause represent 60% of early pre-orders If you want to understand how continuous hormone visibility reshapes female health decisions across life stages, this episode connects biosensing, AI modeling, and practical insights for longevity. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

GLP‑1 Gene Therapy: A One‑Time Fix for Obesity & Diabetes? | Longevity News Roundup — Week 21, 2026

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: https://partners.fatty15.com/UNLOCKED [https://partners.fatty15.com/UNLOCKED] ---------- In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick examine pancreatic cancer immunotherapy, GLP-1 gene therapy, immune system rebuilding, cardiovascular plaque reversal and microbiome medicine. * MatterBio filed its first IND application for Lm-LLO-TT, an engineered Listeria-based therapy targeting pancreatic ductal adenocarcinoma. Pending FDA clearance, the company plans a Phase 1/2a study evaluating safety, dosing and early efficacy in advanced pancreatic cancer patients resistant to conventional immunotherapy. * Fractyl Health received European approval to begin a first-in-human Phase 1/2 trial of RJVA-001, GLP-1 gene therapy for obesity and type 2 diabetes. The therapy uses endoscopic ultrasound-guided pancreatic delivery to program beta cells to produce GLP-1 in response to meals rather than relying on repeated injections. * Ossium Health presented clinical trial data showing successful engraftment using cryopreserved bone marrow collected from deceased organ donors. Researchers believe the banking platform could eventually simplify bone marrow transplantation logistics and expand future immune system renewal applications. * Cyclarity shared new progress on therapies targeting 7-ketocholesterol, an oxidized cholesterol molecule linked to plaque instability and chronic arterial inflammation. Rather than slowing plaque growth, the company aims to physically remove toxic cholesterol deposits already embedded within blood vessel walls. * Microbiotica reported positive Phase 1b MELODY-1 trial data for MB097, a microbiome therapy containing nine bacterial strains combined with KEYTRUDA in advanced melanoma patients. The therapy showed successful gut engraftment and encouraging signals that microbiome modulation may help overcome immunotherapy resistance. * The episode also explored health equity in longevity medicine with Poonam Desai ahead of The Longevity Show. Discussions focused on sex-specific medicine, unequal access to longevity care and the risks of building precision health systems around biased clinical data. ---------- News & References: * ‘Rebuilding the human immune system is possible’ → https://longevity.technology/news/rebuilding-the-human-immune-system-is-possible/ [https://longevity.technology/news/rebuilding-the-human-immune-system-is-possible/] * Fractyl Health to begin EU trials for one-time weight loss gene therapy → https://longevity.technology/news/fractyl-health-to-begin-eu-trials-for-one-time-weight-loss-gene-therapy/ [https://longevity.technology/news/fractyl-health-to-begin-eu-trials-for-one-time-weight-loss-gene-therapy/] * Matter Bio takes pancreatic therapy to clinic → https://longevity.technology/news/matter-bio-takes-pancreatic-therapy-to-clinic/ [https://longevity.technology/news/matter-bio-takes-pancreatic-therapy-to-clinic/] * New data suggests plaque damage can be cleared → https://longevity.technology/news/new-data-suggests-plaque-damage-can-be-cleared/ [https://longevity.technology/news/new-data-suggests-plaque-damage-can-be-cleared/] * Microbiome medicine moves past wellness into clinics → https://longevity.technology/news/microbiome-medicine-moves-past-wellness-into-clinics/ [https://longevity.technology/news/microbiome-medicine-moves-past-wellness-into-clinics/] * ‘Equity in longevity is the entire ballgame’ → https://longevity.technology/news/equity-in-longevity-is-the-entire-ballgame/ [https://longevity.technology/news/equity-in-longevity-is-the-entire-ballgame/]